Evidence map›Paper›PMID 42177260›Full record

Observational studyScientific reports2026

Carbapenem-resistant Gram-negative bacilli infections in Japanese patients with cancer.

Naoya Itoh, Takanori Kawabata, Nana Akazawa, Kayoko Hayakawa, Masahiro Suzuki, Aki Sakurai, Kohei Uemura, Yasufumi Matsumura, Ryota Hase, Hideaki Kato and 6 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Naoya ItohDivision of Infectious Diseases, Aichi Cancer Center Hospital, Aichi , Nagoya, Japan. itohnaoya0925@ybb.ne.jp.
Takanori KawabataDepartment of Data Science, National Cerebral and Cardiovascular Center, Osaka, Japan.
Nana AkazawaDivision of Infectious Diseases, Aichi Cancer Center Hospital, Aichi , Nagoya, Japan.
Kayoko HayakawaDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Masahiro SuzukiDepartment of Microbiology, Fujita Health University School of Medicine, Toyoake, Japan.
Aki SakuraiDepartment of Microbiology, Fujita Health University School of Medicine, Toyoake, Japan.
Kohei UemuraInterfaculty Initiative in Information Studies, The University of Tokyo, Tokyo, Japan.
Yasufumi MatsumuraDepartment of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Ryota HaseDepartment of Infectious Diseases, Japanese Red Cross Narita Hospital, Chiba, Japan.
Hideaki KatoInfection Prevention and Control Department, Yokohama City University Hospital, Kanagawa, Yokohama, Japan.
Takehiro HashimotoHospital Infection Control Center, Oita University Hospital, Oita, Japan.
Takashi MatonoDivision of Infectious Disease and Hospital Epidemiology, Saga University Hospital, Saga, Japan.
David van DuinDivision of Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA.
Norio OhmagariDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Yohei DoiDepartment of Microbiology, Fujita Health University School of Medicine, Toyoake, Japan.
Sho SaitoDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Funding

Japan Society for the Promotion of Science JP22K10547Japan Society for the Promotion of Science JP22K17408NCGM Intramural Research Fund 22A1007Outstanding Research Group Support Program in Nagoya City University 2530003
6 · The paper itself

Abstract

Carbapenem-resistant bacteria represent a significant challenge for patients with cancer; however, the characteristics and prognoses of carbapenem-resistant Gram-negative bacilli (CRGNB) infections in Japanese patients with cancer remain unclear. Therefore, we aimed to investigate the features and outcomes of CRGNB infections in this population. This multicenter prospective observational cohort study prospectively enrolled 167 patients with CRGNB infections, with or without cancer from April 2019 to March 2022. The 30-day mortality rate was numerically higher, although not significantly (18.2% vs. 14.0%, p = 0.45), in the cancer group than in the non-cancer group. The average length of hospital stay was similar (44.6 days vs. 51.0 days, p = 0.55). Similarly, the incidence of the composite outcome-defined as the 30-day mortality or events associated with worsening clinical course-was also not significantly different (56.1% vs. 43.6%, p = 0.12). Propensity score analysis using inverse probability weighting showed no significant difference in the 30-day mortality and average length of hospital stay (p = 0.25 and 0.66). However, the incidence of the composite outcome was significantly higher in the cancer group (odds ratio, 2.36; p = 0.02). Patients with cancer and CRGNB infection experienced worse composite outcomes than those without cancer, highlighting the need for preventive measures for CRGNB infections in this population.

Indexed as

CarbapenemsGram-Negative BacteriaGram-Negative Bacterial InfectionsNeoplasmsAgedAged, 80 and overAnti-Bacterial AgentsEast Asian PeopleFemaleHumansJapanLength of StayMaleMiddle AgedProspective StudiesAnti-Bacterial AgentsCarbapenemsCancerCarbapenem-resistant bacteriaClinical outcomesGram-negative bacilliJapanMultidrug-resistant infections

Identifiers

PMID42177260
PMCPMC13421464

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.